US20070066850A1 - Catalysts - Google Patents

Catalysts Download PDF

Info

Publication number
US20070066850A1
US20070066850A1 US10/564,902 US56490204A US2007066850A1 US 20070066850 A1 US20070066850 A1 US 20070066850A1 US 56490204 A US56490204 A US 56490204A US 2007066850 A1 US2007066850 A1 US 2007066850A1
Authority
US
United States
Prior art keywords
hydrogen
catalyst according
phos
group
chiral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/564,902
Inventor
William Hems
Gabriela Grasa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johnson Matthey PLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Assigned to JOHNSON MATTHEY PLC reassignment JOHNSON MATTHEY PLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HEMS, WILLIAM PATRICK, GRASA, GABRIELA ALEXANDRA
Publication of US20070066850A1 publication Critical patent/US20070066850A1/en
Priority to US12/696,736 priority Critical patent/US8039675B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14Nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0046Ruthenium compounds
    • C07F15/0053Ruthenium compounds without a metal-carbon linkage

Definitions

  • group 8 transition metal catalysts of the present invention include but are not limited to the following;

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Catalysts suitable for asymmetric hydrogenation reactions is described comprising the reaction product of a group (8) transition metal compound a chiral phosphine and a chiral diamine of formula (1) in which R1, R2 R3 or R4 are independently hydrogen, a saturated or unsaturated alkyl, or cycloalkyl group, an aryl group, a urethane or sulphonyl group and R5, R6, R7 or R8 are independently hydrogen, a saturated or unsaturated alkyl or cycloalkyl group, or an aryl group, at least one of R1, R2, R3 or R4 is hydrogen and A is a linking group comprising one or two substituted or unsubstituted carbon atoms.
Figure US20070066850A1-20070322-C00001

Description

  • This invention relates to transition metal catalysts for performing asymmetric hydrogenation reactions and in particular to transition metal catalysts for the asymmetric hydrogenation of ketones and imines.
  • Transition metal catalysts particularly those based on chiral ruthenium (Ru) phosphine complexes are known to be effective for the asymmetric hydrogenation of ketones. EP-B-0718265 describes the use of chiral Ru-bis(phosphine)-1,2-diamine complexes for the hydrogenation of ketones to produce chiral alcohols. Similarly, WO 01174829 describes a chiral Ru-Phanephos-1,2-diamine complex for the asymmetric hydrogenation of ketones.
  • Although it is accepted that the combination of bis(phosphine) and the chiral diamine ligands are important for achieving a high enantiomeric excess (ee) and a wide range of phosphine ligands has been described, only 1,2-diamine ligands have been widely used heretofore. By the term “1,2-diamines” we mean diamines wherein the carbon atoms to which the amine functionalities are bound are directly linked. Such diamines include chiral substituted ethylenediamine compounds such as (S,S)-diphenylethylenediamine ((S,S)-Dpen). Without wishing to be bound by any theory we believe that this is due to the perceived need for the resulting conformationally-stable 5-membered ring structure that forms when 1,2-diamines coordinate to the metal atom. Larger ring structures, for example those formed using 1,3- or 1,4-diamines can be less conformationally-stable and therefore may be expected to provide catalysts that give lower enantiomeric excesses than the corresponding catalysts prepared using 1,2-diamines.
  • Accordingly the chiral catalysts used heretofore comprise 1,2-diamines and have relied principally upon variation of the structure of the phosphine ligand to improve their enantioselectivity. Although effective for some substrates such as acetophenone, a range of ketone and imine substrates remain unreactive to the existing catalysts or are obtained with undesirably low enantiomeric excesses.
  • We have found surprisingly that chiral catalysts suitable for the hydrogenation of ketones and imines may comprise diamines that provide larger ring structures and that such catalysts can provide higher enantiomeric excesses than those comprising 1,2-diamines.
  • Accordingly the invention provides a chiral catalyst comprising the reaction product of a group 8 transition metal compound a chiral phosphine and a chiral diamine of formula (I)
    Figure US20070066850A1-20070322-C00002
  • In which R1, R2, R3 or R4 are independently hydrogen, a saturated or unsaturated alkyl, or cycloalkyl group, an aryl group, a urethane or sulphonyl group and R5, R6, R7 or R8 are independently hydrogen, a saturated or unsaturated alkyl or cycloalkyl group, or an aryl group, at least one of R1, R2, R3 or R4 is hydrogen and A is a linking group comprising one or two substituted or unsubstituted carbon atoms.
  • The group 8 transition metal compound may be a compound of cobalt (Co), nickel (Ni), ruthenium, (Ru), rhodium (Rh), iridium (I), palladium (Pd) or platinum (Pt). For hydrogenation of ketones and imines the transition metal compound is preferably a compound of ruthenium.
  • The metal compound may be any metal compound that is able to react with the phosphine and the chiral diamine (I) to provide a metal complex catalyst. The metal compound is preferably a metal salt, e.g. halide, carboxylate, sulphonate or phosphonate, or an organometallic compound. Particularly suitable metal compounds include [RuCl2(benzene)]2 and [RuCl2(cymene)]2.
  • The chiral phosphine may be a monodentate or bidentate phosphine. Preferably the chiral phosphine is a chiral bis(phosphine). A range of chiral bis(phosphines) are known and may be used in the present invention. Suitable chiral bis(phosphines) include but are not restricted to the following structural types;
    Figure US20070066850A1-20070322-C00003
    Figure US20070066850A1-20070322-C00004
  • Preferably, the chiral phosphine is based on BINAP, DUPHOS, PHANEPHOS, and P-PHOS, more preferably BINAP where R=Tolyl (tol-BINAP) or P-PHOS where R=Phenyl (P-PHOS), tolyl (tol-P-PHOS) or Xylyl (xyl-P-PHOS) and especially xyl-P-PHOS.
  • The chiral diamine is of formula (I)
    Figure US20070066850A1-20070322-C00005
  • in which R1, R2, R3 or R4 are independently hydrogen, a saturated or unsaturated alkyl, or cycloalkyl group, an aryl group, a urethane or sulphonyl group and R5, R6, R7 or R8 are independently hydrogen, a saturated or unsaturated alkyl or cycloalkyl group, or an aryl group, at least one of R1, R2, R3 or R4 is hydrogen and A is a linking group comprising one or two substituted or unsubstituted carbon atoms.
  • Alkyl groups may be straight chain or branched alkyl groups (e.g. C1-C20) such as methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, dodecyl, and stearyl, “cycloalkyl” is meant to encompass (e.g. C3-C10) cycloalkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or adamantly., Aryl groups may be phenyl (Ph), naphthyl (Np) or anthracyl and heteroaryl groups such as pyridyl. The alkyl groups may be optionally substituted with one or more substituents such as halide (Cl, Br, F or I) or alkoxy groups, e.g. methoxy, ethoxy or propoxy groups. The aryl groups may be optionally substituted with one or more substituent such as halide (Cl, Br, F or I), alkyl (C1-C20) alkoxy (C1-C20), amino (NR2, where R=hydrogen or alkyl), hydroxy, halide (e.g. Cl, Br or F), carboxy (CO2R′, R′═H or alkyl) or sulphonate groups. Suitable substituted aryl groups include 4-methylphenyl(tolyl), 3,5-dimethylphenyl(xylyl), 4-methoxyphenyl and 4-methoxy-3,5-dimethylphenyl.
  • R1, R2, R3 and R4 may be the same or different and are preferably selected from hydrogen or methyl, ethyl, isopropyl, cyclohexyl, phenyl or 4-methylphenyl groups.
  • In one embodiment, R1 and R2 are linked or R3 and R4 are linked so as to form a 4 to 7-membered ring structure, preferably a 5- or 6-membered ring structure, incorporating the nitrogen atom.
  • Most preferably R1, R2, R3, R4 are the same and are hydrogen.
  • R5, R6, R7 and R8 may be the same or different and are preferably hydrogen, methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, sec-butyl, tert-butyl, cycloalkyl groups such as cyclohexyl, aryl groups such as substituted or unsubstituted phenyl or naphthyl groups.
  • In one embodiment one or more of R5, R6, R7 or R8 may form one or more ring structures with the linking group A. The ring structure may comprise an alkyl or heteroalkyl 4- to 7-membered ring, preferably a 5- or 6-membered ring or may be an aromatic ring structure, e.g. aryl or hetero-aryl.
  • In EP-B-0718265 it was suggested that the nitrogen atoms of the diamine should be bound to chiral centres (centers of asymmetricity, p7, line line 2). We have found surprisingly that the chirality need not reside in these carbon atoms but may suitably be present in other parts of the diamine molecule, e.g. within R5, R6, R7 or R8 or linking group A.
  • The diamine ligand (I) is chiral. Preferably R5, R6, R7 or R8 or linking group A are chosen such that the ligand may be homochiral, i.e. (R,R) or (S,S) or have one (R) and one (S) centre. Preferably the chiral diamine is homochiral.
  • Linking group A provides a link between the carbon atoms to which the amine groups —NR1R2 and —NR3R4 are bound and comprises one or two substituted or unsubstituted carbon atoms. Substituting groups may replace one or both hydrogen atoms on the carbon atoms. The substituting groups may comprise one or more alkyl (C1-C20), alkoxy (C1-C20) or amino (NR2, where R=hydrogen or alkyl) groups. The substituting groups may form one or more ring structures, e.g. a 4 to 7-membered ring structures incorporating one or more carbon atoms making up the linking group. Thus linking group A may comprise one or two carbon atoms forming part of one or more aromatic ring structures.
  • In one embodiment, the diamine is of formula (II)
    Figure US20070066850A1-20070322-C00006
  • wherein R1, R2, R3, R4, R5, R6, R7 and R8 are as previously described and B is a linking group comprising one or two substituted or unsubstituted carbon atoms. Preferably R1, R2, R3, R4 are hydrogen, R5, R6, R7 and R8 are hydrogen or alkyl groups and B comprises C(CH3)2 or (CH3)(OCH3)C—C(CH3(OCH3).
  • In a further embodiment, the diamine is of formula (III)
    Figure US20070066850A1-20070322-C00007
  • wherein R1, R2, R3, R4, R5, R7 and R8 are as previously described and R′ is a protecting group. Preferably R1, R2 and R5 are hydrogen, R3 and R4 are hydrogen or alkyl, R7 and R8 are hydrogen, alkyl or aryl. It will be understood by persons skilled in the art that a wide range of protecting groups R′ may be used for example alkyl, aryl, carboxylate, amido or sulphonate protecting groups may be used, e.g. benzyl (CH2C6H5), methyl, tert-butyl, allyl, phenyl and substituted phenyls, CO2C(CH3)3 (Boc), CO2CH2C6H5 (Cbz), ethyl carbonate, formamide, acetamides, benzamides, tosyl (Ts) and mesyl (Ms).
  • In a further embodiment, the diamine is of formula (IV)
    Figure US20070066850A1-20070322-C00008
  • wherein R1, R2, R3, R4, R5, R6, R7 and R8 are as previously described. Preferably R1, R2, R3, R4, R6, R7 are hydrogen and R5 and R8 are aryl or substituted aryl, most preferably C6H5.
  • In a further embodiment, the diamine has R1, R2, R3, R4 as hydrogen and is of formula (V)
    Figure US20070066850A1-20070322-C00009
  • wherein R5 and R8 are as previously described and n=1 or 2. Preferably R5 and R8 are hydrogen.
  • Thus suitable chiral diamines include but are not restricted to the following;
    Figure US20070066850A1-20070322-C00010
    Figure US20070066850A1-20070322-C00011
  • Particularly preferred diamines are PyrBD, DioBD, DAMTAR and dppn, more preferably PyrBD and DioBD, especially PyrBD.
  • We have found particularly effective combinations of bisphosphine, Group 8 metal and diamine of the present invention. Accordingly, group 8 transition metal catalysts of the present invention include but are not limited to the following;
    Figure US20070066850A1-20070322-C00012
  • Particularly preferred catalysts are;
      • (i) (bisphosphine)RuCl2-PyrBD catalysts where the bisphosphine is selected from the list comprising tol-BINAP and xyl-P-PHOS,
      • (ii) (bisphosphine)RuCl2-DioBD catalysts where the bisphosphine is selected from the list comprising tol-BINAP, and
      • (iii) Xyl-P-PHOSRu(diamine) catalysts where the diamine is selected from the list consisting of dppn, PyrBd, DAMTAR and DioBD, particularly dppn.
      • These catalysts have been found to be more active and/or selective that their 1,2-diamine counterparts and other combinations of bisphosphine and diamine of the present invention.
  • The catalysts of the present invention may be readily prepared from the metal compound, phosphine and diamine. In general, the metal compound is combined with the phosphine in a suitable solvent and heated if necessary and then the diamine is added to form the desired metal complex catalyst. For example, P-PHOS compounds react under relatively mild conditions with [RuCl2(benzene)2]2 and then 1,3-Dppn to form catalysts suitable for performing asymmetric hydrogenation reactions. This reaction is depicted below.
    Figure US20070066850A1-20070322-C00013
  • The chiral metal complex catalysts of the present invention may be applied to a number of asymmetric reactions used to produce chiral products. Such reactions include but are not limited to the asymmetric hydrogenation of ketones and imines. To achieve high levels of enantiomeric purity in the reaction it is preferred that the metal complex comprises a substantially enantiomerically-pure phosphine and 1,3- or 1,4-diamine ligands of the present invention.
  • The conditions for using the metal complex catalysts are typically similar to those used for structurally related catalysts. For example, for the asymmetric reduction of ketones, the above catalyst may be used at room temperature under standard hydrogen pressures in combination with a strong base such as a sodium or potassium alkoxide, e.g. potassium tert-butoxide (KOtBu) to yield chiral alcohols in high yield and enantiomeric excess.
  • Ketones and imines that may be reduced using catalysts of the present invention may be of formula RCXR′ in which R and R′ are substituted or unsubstituted, saturated or unsaturated alkyl, cycloalkyl or aryl groups which may be linked and form part of a ring structure, e.g. a 5 or 6 membered ring structure, and X is O (Oxygen) or NR″ in which R″ may be alkyl, cycloalkyl or aryl which may be linked to R and/or R′ as part of a ring structure.
  • We have found that the chiral catalysts of the present invention are able to catalyse the hydrogenation of alkyl- as well as aryl-ketones. Hydrogenation of alkyl-ketones, e.g. pinacolone, octanone, hexanone and cyclohexanone is extremely attractive and has not been successfully achieved with chiral bisphosphine ruthenium diamine catalysts heretofore. Thus a preferred use of the chiral catalysts of the present invention is the hydrogenation of alkyl ketones of formula RCOR′ in which R and R′ above are C1-C20 substituted or unsubstituted, saturated or unsaturated alkyl or cycloalkyl which may be linked and form part of a ring structure, e.g. a 5 or 6 membered ring structure.
  • The invention is further illustrated by reference to the following examples. Unless otherwise stated room temperature was 20-25° C.
  • EXAMPLE 1 Synthesis of Diphenyl-1,3-propanediamine (Dppn)
  • The diamine was prepared by the procedure of Roos et al. (Tetrahedron: Asymmetry 1999, 991-1000). The diol was prepared by transfer hydrogenation of the diketone by the procedure of Cossy (Tetrahedron Letters, 2001, 5005-5007).
    Figure US20070066850A1-20070322-C00014
  • A mixture of dibenzyloylmethane (2.5 g, 0.0117 mol), [RuCl(cymene)(R,R)Ts-Diphenylethylenediamine] (78 mg, 0.117 mmol) in triethylamine/formic acid azeotropic mix (5:2, 0.0234 mol) and dichloromethane (10 ml) was heated at 40° C. for 48 hrs. The solvent was removed in vacuo and the residue poured into water (100 ml) which resulted in the precipitation of a colourless solid. The solid was dried and used in the next step without further purification.
  • (b) 1,3-Diphenyl-1,3-Propanediazide
  • To the chiral 1,3-Diphenyl-1,3-Propanediol (0.150 g, 0.664 mmol) and triethylamine (0.205 g, 2.03 mmol) in tetrahydrofuran (THF) (5 ml) at 0° C. under nitrogen was added methanesulfonyl chloride (0.102 ml, 1.33 mmol). The mixture was allowed to warm to room temperature and stirred for 1 hr. The mixture was then filtered and the solid washed with a further portion of THF (5 ml). The solvent was then removed in vacuo to leave the crude product. To this crude product was added dimethylformamide (DMF) (2 ml) and sodium azide (0.135 g, 2.08 mmol) and the mixture stirred at room temperature overnight. Thin layer chromatography (TLC) indicated complete conversion of the starting material. The DMF was removed in vacuo and methyl-tert-butyl ether (MTBE) added (25 ml). The organic layer was washed with water (25 ml) and brine (25 ml). The solvent was removed to yield the diazide as a colourless solid.
  • 1H NMR (CDCl3, 400 MHz) δ 7.7-7.0 (10H, m, Ar—H), 4.7 (2H, t, CH), 2.0 (2H, t, CH2).
  • (c) 1,3-Diphenyl-1,3-Propanediamine (dppn)
  • A mixture of the diazide (0.1 g, 2.79 mmol) and Pd/C (10 wt % Pd, 0.010 g) was stirred in an autoclave under hydrogen gas (80 psi) for 2 hrs. The hydrogen was released and the mixture filtered through celite. The solvent was removed to give the diamine as initially a colourless solid which was recrystallised by using a minimum amount of chloroform.
  • 1H NMR (CDCl3, 400 MHz) δ 7.7-7.0 (10H, m, Ar—H), 3.9 (2H, t, CH), 2.0 (2H, t, CH2).
  • EXAMPLE 2 Preparation of Dppn-Catalysts a) Preparation of Ru[Cl2{(R/S)-Xyl-P-Phos}{(R,R)/(S,S)-DPPN}]
  • Figure US20070066850A1-20070322-C00015
  • A solution of (R)- or (S)-Xyl-P-Phos (100 mg, 0.132 mmol) and [RuCl2(benzene)] dimer (31.5 mg, 0.063 mmol) in Dimethylformamide (1 ml) was heated at 100 C for 2.5 hrs under N2. The dark red reaction mixture was cooled to room temperature. To this crude complex was added a solution of the (R,R)- or (S,S)-Dppn diamine (0.138 mmol) in dichloromethane (1 ml) under nitrogen. The brown solution was stirred at room temperature overnight after which the solvent was removed in vacuo to yield the crude complex as a brown solid.
  • Trans-Ru[Cl2{(R)-Xyl-P-Phos}{(R,R)-DPPN}]. 31P NMR (400 MHz, CDCl3) δ 44.5 (s).
  • Trans-Ru[Cl2{(S)-Xyl-P-Phos}{(R,R)-DPPN}]. 31P NMR (400 MHz, CDCl3) δ 44.5 (s).
  • Trans-Ru[Cl2{(S)-Xyl-P-Phos}{(S,S)-DPPN}]. 31P NMR (400 MHz, CDCl3) δ 44.6 (s).
  • Trans-Ru[Cl2{(R)-Xyl-P-Phos}{(S,S)-DPPN}]. 31P NMR (400 MHz, CDCl3) δ 43.9 (s).
  • b) Preparation of Ru[Cl2{(R)-Xyl-BINAP}{(R,R)-DPPN}]
  • The above experiment was repeated combining (R)-Xyl-BINAP with [RuCl2(benzene)] dimer and reacting this with the (R,R)-Dppn.
  • The crude product was obtained by removal of the solvent. Trans-Ru[Cl2{(R)-Xyl-BINAP}{(R,R)-DPPN}]. 31P NMR (400 MHz, CDCl3) δ 45.3 (s).
  • EXAMPLE 3 Hydrogenation Reactions Using Dppn-Catalysts
  • General method: Asymmetric hydrogenation of ketones (substrate to catalyst S/c ratio 1000/1): 2-propanol (2 mL), ketone (2 mmol) and 0.1 M potassium tert-butoxide (KOtBu) (50 μL, 5×10−3 mmol) were added in turn to a 25 mL autoclave charged with the ruthenium catalyst (2×10−3 mmol), under inert atmosphere. The vessel was first purged with hydrogen three times and then pressurised with hydrogen to 8.3 bar. The reaction mixture was stirred at room temperature for the indicated time. The enantiomeric excess was determined by gas-chromatography using a Chirasil-DEX CB column.
  • Asymmetric hydrogenation of ketones (substrate to catalyst ratio=2500/1): 2-propanol (4.4 mL), ketone (5 mmol) and 0.1 M KOtBu (50 μL, 5×10−3 mmol) were added in turn to a 25 mL autoclave charged with the ruthenium catalyst (2×10−3 mmol), under inert atmosphere. The vessel was first purged with hydrogen three times and then pressurized with hydrogen to 145 psi. The reaction mixture was stirred at room temperature for the indicated time. The enantiomeric excess was determined by gas-chromatography using a Chirasil-DEX CB column.
  • a) Hydrogenation of Acetophenone
  • Figure US20070066850A1-20070322-C00016
    Figure US20070066850A1-20070322-C00017
    Using the general method, the Dppn-catalysts of
    Example 2 gave the following results;
    Time
    Catalyst S/c (hrs) Conv. (%) Ee (%)
    (R)Xyl-P-Phos-RuCl2-(R,R)-Dppn 1000 3 100 93
    (R)Xyl-P-Phos-RuCl2-(R,R)-Dppn 2500 3 100 95
    (R)Xyl-P-Phos-RuCl2-(R,R)-Dppn 2500 2.5 100 95
    (R)Xyl-P-Phos-RuCl2-(R,R)-Dppn 2500 6.5 95 95
    (S)Xyl-P-Phos-RuCl2-(R,R)-Dppn 1000 5 100 69
    (S)Xyl-P-Phos-RuCl2-(R,R)-Dppn 2500 6 100 74
    (R)Xyl-P-Phos-RuCl2-(R,R)-Dppn  1000# 12 100 95
    (S)Xyl-P-Phos-RuCl2-(S,S)-Dppn  2500# 12 100 95
    (S)Xyl-P-Phos-RuCl2-(S,S)-Dppn 10000* 24 100 95.3

    #Hydrogenated at 10 bar

    *General method as for S/c 2500/1
  • In comparison to Xyl-P-Phos, when unsubstituted (R)-P-Phos was used as the chiral bisphosphine in combination with (R,R)-Dppn, the ruthenium catalyst was less selective and after a reaction time of 18 hours gave a lower ee of 36%. This result shows the particular effectiveness of the combination of xyl-P-Phos and dppn in the Ru catalysed hydrogenation of aryl ketones.
  • b) Hydrogenation of Substituted Acetophenones
  • Using the general methods described in Example 3, hydrogenation was performed at 10 bar hydrogen on 2-propanol solutions of substituted acetophenones using (R)Xyl-P-Phos-RuCl2—(R,R)-Dppn or (S)Xyl-P-Phos-RuCl2—(S,S)-Dppn. The base/catalyst ratio was 50/1 for all. THe results are given below;
    Figure US20070066850A1-20070322-C00018
    Figure US20070066850A1-20070322-C00019
    Ketone Catalyst S/c Time (h) Conv. (%) Ee (%)
    R = p-F (S, SS) 2500 14 >99 95
    R = p-OMe (S, SS) 2500 14 >99 97.3
    R = m-Me (S, SS) 2500 12 >99 96.4
    R = o-Me (R, RR) 1000 20 >99 86
    R = o-OMe (R, RR) 1000 24 >99 84
    R = bis 3,5-CF3 (S, SS) 1000 10 >99 95.7
  • The results show the catalysts to give good selectivities irrespective of the presence of electron donating or withdrawing substituents on the para or meta positions.
  • c) Hydrogenation of Pinacolone
  • Figure US20070066850A1-20070322-C00020
  • Using the general method with the Dppn-catalysts of Example 2 gave the following results;
    Time
    Catalyst S/c (hrs) Conv (%). Ee (%)
    (R)Xyl-P-Phos-RuCl2-(R,R)-Dppn 1000 16 46 65
    (R)Xyl-BINAP-RuCl2-(R,R)-Dppn 1000 16 48 60
  • A comparative experiment was performed using the general method with a comparative 1,2-diamine catalyst based on 1,2-diphenylethylenediamine (Dpen).
    Time
    Comparative Catalyst S/c (hrs) Conv (%). Ee (%)
    (R)Xyl-BINAP-RuCl2-(R,R)-Dpen 1000 16 30 11
  • The results demonstrate that the Dppn-catalysts of Example 2 can give an improved yield and enantiomeric excess over the comparative 1,2-diamine catalyst.
  • EXAMPLE 4 Synthesis of (3-Aminomethyl-5-6-dimethoxy-5-6-Dimethyl[1,4]-dioxan-2-yl]-methylamine [(S,S)-DioBD]
  • The intermediate diol was prepared according to literature procedure for steps (a) and (b). (Ley, J. Chem. Soc., Perkin Trans 1, 1999, 1627).
    Figure US20070066850A1-20070322-C00021
  • EXAMPLE 5 Preparation of DioBD Catalysts (a) Preparation of Ru[Cl2{(R/S)-Tol-BINAP}{(S,S)-DioBD}]
  • Figure US20070066850A1-20070322-C00022
  • A solution of (R)- or (S)-TolBinap (100 mg, 0.147 mmol) and [RuCl2(benzene)] dimer (37 mg, 0.0737 mmol) in Dimethylformamide (1 ml) was heated at 110° C. for 15 mins under N2. The dark red reaction mixture was cooled and the dmf removed in vacuo. To this crude complex was added a solution of the (S,S)-DioBD diamine (34 mg, 0.147 mmol) in dichloromethane (5 ml) under nitrogen. The yellowish solution was stirred at room temperature for 1 hr after which the solvent was removed in vacuo. The complex was extracted from the crude solid by addition of hexane:MTBE (1:1, 10 ml), filtration and removal of the solvent which resulted in the precipitation of a yellow solid. The solvent was completely removed and to give the complex as a yellow solid.
  • Ru[Cl2{(S)-Tol-BINAP}{(S,S)-DioBD}]: 31P NMR (CDCl3, 400 MHz) δ 44.8
  • Ru[Cl2{(R)-Tol-BINAP}{(S,S)-DioBD}]: 31P NMR (CDCl3, 400 MHz) δ 45.4
  • EXAMPLE 6 Hydrogenation Reactions Using DioBD-Catalysts (a) Hydrogenation of Tetralone
  • Figure US20070066850A1-20070322-C00023
  • 2-propanol (1 mL), tetralone (1 mmol) and 0.1 M KOtBu (50 μL, 5×10−3 mmol) were added in turn to a 25 mL autoclave charged with the ruthenium catalyst (2×10−3 mmol), under inert atmosphere. The vessel was first purged with hydrogen three times and then pressurized with hydrogen to 8.3 bar. The reaction mixture was stirred at room temperature for the indicated time. The enantiomeric excess was determined by GC using a Chirasil-DEX CB column. Using this method, the DioBD-catalyst of Example 5 gave the following results;
    Time
    Catalyst S/c (hrs) Conv. (%) Ee (%)
    (S)TolBINAP-RuCl2-(S,S)-DioBD 500 16 23.5 81
  • A comparative experiment was performed using the same method with a comparative 1,2-diamine catalyst based on 1,2-diphenylethylenediamine (Dpen).
    Time
    Comparative Catalyst S/c (hrs) Conv. Ee (%)
    (S)TolBINAP-RuCl2-(S,S)-Dpen 500 16 98 24
  • The result demonstrates that the DioBD-catalysts of Example 5 can give an improved enantiomeric excess over the comparative 1,2-diamine catalyst.
  • EXAMPLE 7 Synthesis of (2S,4S)-4-Amino-2-aminomethylpyrrolidine-1-carboxylic acid tert-butyl ester (PyrBD)
  • The synthesis is based on the commercially available trans diol. Ganesh (Organic Letters, 2001,3, 103), has reported the synthesis of these diamines for use as analogues that stabilise DNA duplexes and triplexes.
    Figure US20070066850A1-20070322-C00024
  • (2S,4R)-4-Methanesulfonyloxy-2-methanesulfonyloxymethylpyrrolidine-1-carboxylic acid tert-butyl ester: To a solution of alcohol (˜15 mmol) and triethylamine (6.5 mL, 45 mmol) in THF (100 mL) was slowly added mesylchloride (MsCi) (2.6 mL, 33 mmol). After stirring for 30 min at room temperature, the precipitated salts were filtered off and the reaction mixture was treated with saturated aqueous NH4Cl (100 mL). The aqueous phase was extracted with MTBE (2×75 mL). The combined organic layers were washed with saturated aqueous NaHCO3 (100 mL) and brine (100 mL), dried over anhydrous MgSO4 and concentrated under reduced pressure to afford 4.67 g (12.5 mmol, 83%) of a white solid which was used without further purification.
  • (i) (2S,4S)-4-Azido-2-azidomethylpyrrolidine-1-carboxylic acid tert-butyl ester: A solution of mesylate (4.67 g, 12.5 mmol) and NaN3 (2.43 g, 37.5 mmol) in DMF (50 mL) was heated at 90° C. for 24 hrs. After cooling down to room temperature, the reaction mixture was diluted with MTBE (50 mL) and washed with H2O (5×50 mL). The organic phase was then dried (anhydrous MgSO4) and concentrated under reduced pressure to afford a solid which was used without further purification. 1H NMR (CDCl3, 400 MHz) δ 4.1 (1H, br s), 3.9 (1H, br m), 3.65 (1H, br s), 3.5-3.2 (3H, br m), 2.2 (1H, m), 2.0 (1H, m), 1.4 (9H, s).
  • (ii) (2S,4S)-4-Amino-2-aminomethylpyrrolidine-1-carboxylic acid tert-butyl ester. A mixture of the diazide (0.8 g, 2.79 mmol) and Pd/C (10 wt % Pd, 0.025 g) was stirred in an autoclave under hydrogen (80 psi) for 2 hrs. The hydrogen pressure was released and the mixture filtered through celite. The solvent was removed to give the diamine as a colourless oil.
  • 1H NMR (CDCl3, 400 MHz) δ 3.75 (2H, br s), 3.4 (1H, m), 3.0-2.7 (3H, m), 2.25 (1H, m), 1.5-1.3 (10H, m).
  • EXAMPLE 8 Preparation of PyrBD Catalysts a) Preparation of Ru[Cl2{(R/S)-Tol-BINAP}{(S,S)-PyrBD}]
  • Figure US20070066850A1-20070322-C00025
  • A solution of (R)- or (S)-Tol-Binap (100 mg, 0.147 mmol) and [RuCl2(benzene)] dimer (37 mg, 0.0737 mmol) in Dimethylformamide (1 ml) was heated at 105° C. for 15 mins under nitrogen. The dark red reaction mixture was cooled and the DMF removed in vacuo. To this crude complex was added a solution of the (S,S)-PyrBD diamine (34 mg, 0.147 mmol) in dichloromethane (5 ml) under nitrogen. The yellowish solution was stirred at room temperature for 1 hr after which the solvent was removed in vacuo. The complex was extracted from the crude solid by addition of hexane:MTBE (1:1, 10 ml), followed by filtration and removal of the solvent which resulted in the precipitation of a yellow solid. The solvent was removed under vacuo to give the complex as a yellow solid.
  • Ru[Cl2{(R)-Tol-BINAP}{(S,S)-PyrBD}]: 31P NMR (CDCl3, 400 MHz) δ 45.2 (d, J 37) and δ 41.3 (d, J 37)
  • Ru[Cl2{(S)-Tol-BINAP}{(S,S)-PyrBD}]: 31P NMR (CDCl3, 400 MHz) δ 44.5 (d, J 37) and δ 42.3 (d, J 37)
  • b) Preparation of Ru[Cl2{(R/S)-Xyl-P-Phos}{(S,S)-PyrBD}]
  • Figure US20070066850A1-20070322-C00026
  • A solution of (R)- or (S)-Xyl-P-Phos (51 mg, 0.066 mmol) and [RuCl2(benzene)] dimer (16.8 mg, 0.0315 mmol) in Dimethylformamide (1 ml) was heated at 100° C. for 2.5 hrs under nitrogen. The dark red reaction mixture was cooled to room temperature. To this crude complex was added a solution of the (S,S)-PyrBD diamine (0.067 mmol) in dichloromethane (1 ml) under nitrogen. The brown solution was stirred at room temperature overnight after which the solvent was removed in vacuo to yield the crude complex as a brown solid.
  • Ru[Cl2{(R)-Xyl-P-Phos}{(S,S)-PyrBD}]: 31P NMR (CDCl3, 400 MHz) δ 45.2 (d, J 37) and δ 41.3 (d, J 30)
  • Ru[Cl2{(S)-Xyl-P-Phos}{(S,S)-PyrBD}]: 31P NMR (CDCl3, 400 MHz) δ 44.6 (d, J 37) and δ 41.7 (d, J 37)
  • EXAMPLE 9 Hydrogenation Reactions Using PyrBD-Catalysts a) Hydrogenation of (3′5′)-bis(trifluoromethyl)acetophenone
  • Figure US20070066850A1-20070322-C00027
  • Hydrogenation was performed according to the general method described in Example 3. The PyrBD-catalysts of Example 8 gave the following results;
    Time
    Catalyst S/c (hrs) Conv. (%) Ee (%)
    (S)Xyl-P-Phos-RuCl2-PyrBD 1000 16 >98 69
    (R)Xyl-P-Phos-RuCl2-PyrBD 1000 16 >98 91
  • A comparative experiment was performed using the general method with a comparative 1,2-diamine catalyst based on 1,2-diphenylethylenediamine (Dpen).
    Time
    Comparative Catalyst S/c (hrs) Conv. Ee (%)
    (R)Xyl-P-Phos-RuCl2-(R,R)Dpen 1000 16 >98 60
  • The result demonstrates that the PyrBD-catalysts of Example 8 can give an improved enantiomeric excess over the comparative 1,2-diamine catalyst.
  • b) Hydrogenation of Isobutyrophenone
  • Figure US20070066850A1-20070322-C00028
  • Hydrogenation was performed according to the general method described in Example 3. The PyrBD-catalyst of Example 8 gave the following results;
    Time
    Catalyst S/c (hrs) Conv. (%) Ee (%)
    (S)TolBINAP-RuCl2-(S,S)PyrBD 1000 14 >98 80
  • A comparative experiment was performed using the general method with a comparative 1,2-diamine catalyst based on 1,2-diphenylethylenediamine (Dpen).
    Time
    Comparative Catalyst S/c (hrs) Conv. Ee (%)
    (S)TolBINAP-RuCl2-(S,S)Dpen 1000 48 81 87
  • The result demonstrates that the PyrBD-catalysts of Example 8 can give an improved activity and yield with comparable enantiomeric excess with the comparative 1,2-diamine catalyst.
  • EXAMPLE 10 Preparation of (2S,3S)-2,3-O-isopropylidenebutane 1,4 diamine, DAMTAR
  • Figure US20070066850A1-20070322-C00029
  • A mixture of (S,S),(−) 1,4-Di-O-p-toluolsulphonyl-2,3-O-isopropylidene-L-threitol (1.88 g, 4 mmol) and NaN3 (0.63 g, 10 mmol) in dmf (10 ml) was heated at 80° C. for 24 hrs. The dmf was removed in vacuo and the residue suspended in MTBE (150 ml). The organic layer was washed with water (3×100 ml), brine (100 ml), dried over MgSO4, filtered and the solvent removed by rotary evaporation to give the crude diazide. The product was obtained by column chromatography on silica gel, eluting with hexane:EtOAC (9:1) to give the pure diazide as a colourless liquid.
  • 1H NMR (CDCl3, 400 MHz) δ 3.90 (1H, CH), 3.30 (2H, dddd, CH2), 1.3 (3H, s, CH3); 13C NMR (CDCl3, 100 MHz) δ 110 (C), 76.6 (CH), 51.6 (CH2), 26.8 (CH3).
  • [(S,S) DAMTAR]
  • A mixture of the diazide (0.8 g, 2.79 mmol) and Pd/C (10 wt % Pd, 0.025 g) was stirred in an autoclave under H2 (80 psi) for 2 hrs. The H2 was released and the mixture filtered through celite. The solvent was removed to give the diamine as a colourless oil which eventually solidified upon standing.
  • 1H NMR (CDCl3, 400 MHz) δ 3.7 (1H, CH), 2.7 (2H, m, CH2), 1.25 (3H, s, CH3).
  • EXAMPLE 11 Preparation of DAMTAR Catalysts (a) Preparation of Ru[Cl2{(R/S)-Tol-BINAP}{(R,R/S,S)-DAMTAR}]
  • Figure US20070066850A1-20070322-C00030
  • A solution of (R)- or (S)-Tol-Binap (100 mg, 0.147 mmol) and [RuCl2(benzene)] dimer (37 mg, 0.0737 mmol) in Dimethylforrnamide (1 ml) was heated at 110° C. for 15 mins under N2. The dark red reaction mixture was cooled and the dmf removed in vacuo. To this crude complex was added a solution of the (S,S)-DAMTAR diamine (34 mg, 0.147 mmol) in dichloromethane (5 ml) under nitrogen. The yellow solution was stirred at room temperature for 1 hr after which the solvent was removed in vacuo. The complex was extracted from the crude solid by addition of hexane:MTBE (1:1, 10 ml), filtration and removal of the solvent which resulted in the precipitation of a yellow solid. The solvent was completely removed and to give the complex as a yellow solid.
  • (Ru[Cl2{(R)-Tol-Binap}{(R,R)-DAMTAR}]. 31P NMR (400 MHz, CDCl3) δ 45.5 (s).
  • Ru[Cl2{(R)-Tol-Binap}{(S,S)-DAMTAR}]. 31P NMR (400 MHz, CDCl3) δ 44.8 (s).
  • The method was repeated using (S)-BINAP and (R)- and (S)-Xyl-BINAP. The analyses of the resulting products were as follows;
  • Ru[Cl2{(S)-Binap)}{(R,R-DAMTAR}]. 31P NMR (400 MHz, CDCl3) δ 46.3 (s).
  • Ru[Cl2{(R)-Xyl-Binap}{(R,R)-DAMTAR}]. 31P NMR (400 MHz, CDCl3) δ 45 (s).
  • Ru[Cl2{(S)-Xyl-Binap}{(R,R)-DAMTAR}]. 31P NMR (400 MHz, CDCl3) δ 45.2 (s).
  • Ru[Cl2{(R)-Xyl-Binap}{(S,S)-DAMTAR}]. 31P NMR (400 MHz, CDCl3) δ 45.2 (s).
  • (b) Preparation of Ru[Cl2{(R/S)-Xyl-P-PHOS}}(R,R/S,S)-DAMTAR}]
  • A solution of (R)- or (S)-Xyl-P-PHOS (100 mg, 0.132 mmol) and [RuCl2(benzene)] dimer (31.5 mg, 0.063 mmol) in Dimethylformamide (1 ml) was heated at 100° C. for 2.5 hrs under N2. The dark red reaction mixture was cooled to room temperature. To this crude complex was added a solution of the (R,R)- or (S,S)-DAMTAR diamine (0.138 mmol) in dichloromethane (1 ml) under nitrogen. The brown solution was stirred at room temperature overnight after which the solvent was removed in vacuo to yield the crude complex as a brown solid.
  • Ru[Cl2{(R)-Xyl-P-PHOS}{Cl2(R,R)-DAMTAR}]. 31P NMR (400 MHz, CDCl3) δ 443.7 (s).
  • Ru[Cl2{(S)-Xyl-P-PHOS}{2(R,R)-DAMTAR}]. 31P NMR (400 MHz, CDCl3) δ 43.4 (s).
  • Ru[Cl2{(S)-Xyl-P-PHOS}{2(S,S)-DAMTAR{]. 31P NMR (400 MHz, CDCl3) δ 43.7 (s).
  • The method was repeated using (R)- and (S)—P-PHOS. The analyses of the resulting products were as follows;
  • Ru[Cl2{(R)—P-PHOS}{(R,R)-DAMTAR}]. 31P NMR (400 MHz, CDCl3) δ 45.4 (s).
  • Ru[Cl2{(R)—P-PHOS}{Cl2(S,S)-DAMTAR}]. 31P NMR (400 MHz, CDCl3) δ 44.6 (s).
  • Ru[Cl2{(S)—P-PHOS}{Cl2(R,R)-DAMTAR}]. 31P NMR (400 MHz, CDCl3) δ 44.8 (s).
  • Ru[Cl2{(S)—P-PHOS}{2(S,S)-DAMTAR}]. 31P NMR (400 MHz, CDCl3) δ 45.4 (s).
  • EXAMPLE 12 Hydrogenation Reactions Using DAMTAR Catalysts a) Hydrogenation of isopropyl-phenyl ketone
  • Figure US20070066850A1-20070322-C00031
  • The general hydrogenation procedure of Example 3 was followed. For comparison, a series of 1,2-diamine catalysts were also tested. The results are given below;
    Time Alcohol Conv. Ee
    Catalyst S/C (hrs) Config. (%) (%)
    ((R)-P-Phos)RuCl2(R,R-DAMtar) 1000/1 3 R 100 95
    ((R)-P-Phos)RuCl2(S,S-DAMtar) 1000/1 2.5 R 100 92
    ((S)-P-Phos)RuCl2(R,R-DAMtar) 1000/1 2 S 100 97
    ((S)-P-Phos)RuCl2(S,S-DAMtar) 1000/1 5 S 100 95
    ((S)-P-Phos)RuCl2(R,R-DAMtar) 1000/1 2.5 S 100 93
    ((S)-P-Phos)RuCl2(R,R/S,S-DAMtar) 1000/1 3 S 100 96
    ((R)-P-Phos)RuCl2(R,R/S,S-DAMtar) 1000/1 3 R 100 90-92
    ((S/R-P-Phos)RuCl2(S,S-DAMtar) 1000/1 2 100 9
    ((R)-Xyl-P-Phos)RuCl2(R,R-DAMtar) 1000/1 20 R 100 46
    ((S)-Xyl-P-Phos)RuCl2(R,R-DAMtar) 1000/1 6 S 100 75
    ((R)-Tol-Binap)RuCl2(R,R-DAMtar) 1000/1 5 R 100 90
    ((R)-Tol-Binap)RuCl2(S,S-DAMtar) 1000/1 2 R 100 90
    ((S)-Tol-Binap)RuCl2(S,S-DAMtar) 1000/1 6 S 100 94
    ((S)-Tol-Binap)RuCl2(S,S/R,R-DAMtar) 1000/1 2 S 100 96
    ((S)-Tol-Binap)RuCl2(R,R-DAMtar) 1000/1 2 S 100 97
    ((S)-Tol-Binap)RuCl2(R,R-DAMtar) 1000/1 2.5 S 100 97
    ((S)-Binap)RuCl2(R,R-DAMtar) 1000/1 3.5 S 37 96
    ((R)-Xyl-Binap)RuCl2(R,R-DAMtar) 1000/1 17 R 100 68
    ((S)-Xyl-Binap)RuCl2(R,R-DAMtar) 1000/1 14 S 100 58
    ((S)-Tol-Binap)RuCl2(S,S-DPEN) 1000/1 3.5 R 50 73
    ((S)-P-Phos)RuCl2(S,S-DPEN) 1000/1 3.5
    ((S)-Xyl-P-Phos)RuCl2(S,S-DPEN) 1000/1 3.5 1
    ((S)-PhanePhos)RuCl2(R,R-DPEN) 1000/1 3.5 S 75 68
    ((S)-Xyl-PhanePhos)RuCl2(R,R-DPEN) 1000/1 3.5 R 19 8
  • The results show that excellent selectivities can be obtained using the combination of a phosphine and DAMTAR. Without wishing to be bound by theory it appears that the phosphine may be influencing the selectivity more so that a chiral phosphine in the presence of the racemic diamaine can give high ee.
  • b) Hydrogenation of Tetralone
  • Using the general method of example 3 tatralone was hydrogenated with a range of DAMTAR catalysts. The results are given below;
    Figure US20070066850A1-20070322-C00032
    Figure US20070066850A1-20070322-C00033
    Time (hrs), Alcohol Conv. Ee
    Catalyst S/C Temp. Config. (%) (%)
    (S)-P-Phos)RuCl2(S,S- 250 20, 30° C. R 99 88
    DAMtar)
    ((S)-Xyl-P-Phos)RuCl2 500 20, 40° C. R 27 96
    (R,R-DAMtar)
    ((S)-Xyl-P-Phos)RuCl2 250 0.6, 40° C.  R 99 96
    (R,R-DAMtar)
    ((R)-Tol-Binap)RuCl2 250 48, 30° C. S 98 79
    (R,R-DAMtar)
    ((S)-Binap)RuCl2(R,R- 500 20, 40° C. R 28 86
    DAMtar)
    ((R)-Xyl-Binap)RuCl2 500 20, 40° C. S 55 96
    (S,S-DAMtar)
    ((S)-Xyl-Binap)RuCl2 500 20, 40° C. S 8 87
    (S,S-DAMtar)
  • c) Hydrogenation of Substituted Tetralones
  • Using the general method of Example 3 a series of substituted tetralones were hydrogenated. The results are given below;
    Time conv Ee
    Ketone Catalyst (hrs) (%) (%)
    Figure US20070066850A1-20070322-C00034
    ((S)Xyl-P-Phos)RuCl2(R,R)-DAMtar 0.15 96 91
    Figure US20070066850A1-20070322-C00035
    ((S)Xyl-P-Phos)RuCl2(R,R)-DAMtar 0.4 98 98
    Figure US20070066850A1-20070322-C00036
    ((S)P-Phos)-RuCl2(R,R)-DAMTar 2 99 ≧90 (98:2 syn:anti)
  • The results show that excellent ee s may be obtained using DAMTAR.
  • EXAMPLE 13 Preparation of cis,cis-SpiroDiamine
  • The trans,trans SpiroDiol intermediate was prepared according to literature procedure report by Chan (Tetrahedron Letters, 2000, 4425).
    Figure US20070066850A1-20070322-C00037
  • EXAMPLE 14 Preparation of cis,cis-SpiroDiamine catalysts a) Preparation of Ru[Cl2{(R)-PhanePHOS}{(cis,cis)-SpiroDiamine}]
  • Figure US20070066850A1-20070322-C00038
  • (R)-PhanePHOS (33 mg, 0.058 mmol) and [Ru(benzene)Cl]2 (14.7 mg, 0.0294 mmol) were placed in a Schienk flask and the air was replaced with nitrogen. Anhydrous, degassed DMF (1.5 ml) and toluene (2 ml) were added. The mixture was then heated at 105° C. for 4 hours. A red homogeneous solution was obtained. To the solution was then added solid cis,cis-SpiroDiamine (0.05889 mmol) and the solution heated again for 1.5 hrs at 105° C. The solvent was then removed under vacuo. The resulting solid was dissolved in CH2Cl2 and MTBE added. Removal of the solvent caused precipitation of a tan coloured solid. The solid was not collected but the solvent completely removed to give the crude complex, which was used without any further purification.
  • Ru[Cl2{(R)-Phanephos){}(cis,cis)-SpiroDiamine}]: 31P NMR (CDCl3): 44.68 ppm.

Claims (20)

1. A chiral catalyst comprising the reaction product of a ruthenium compound, a chiral bis(phosphine) selected from P-Phos, tol-P-Phos or xyl-P-Phos and a chiral diamine of formula (I)
Figure US20070066850A1-20070322-C00039
in which R1, R2, R3 or R4 are independently hydrogen, a saturated or unsaturated alkyl, or cycloalkyl group, an aryl group, a urethane or sulphonyl group and R5, R6, R7 or Re are independently hydrogen, a saturated or unsaturated alkyl or cycloalkyl group, or an aryl group, at least one of R1, R2, R3 or R4 is hydrogen and A is a linking group comprising one or two substituted or unsubstituted carbon atoms.
2. (canceled)
3. A catalyst according to claim 1 wherein R1, R2, R3 and R4 are the same or different and are selected from hydrogen, methyl, ethyl, isopropyl, cyclohexyl, phenyl or 4-methylphenyl groups.
4. A catalyst according to claim 1 wherein R1 and R2 are linked or R3 and R4 are linked so as to form a 4 to 7-membered ring structure incorporating the nitrogen atom.
5. A catalyst according to claim 1 wherein R5, R6, R7 and R8 are the same or different and are selected from hydrogen, methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, sec-butyl, tert-butyl, cyclohexyl or substituted or unsubstituted phenyl or naphthyl groups.
6. A catalyst according to claim 1 wherein one or more of R5, R6 R7 or Re form one or more ring structures with the linking group A.
7. A catalyst according to claim 1 wherein a substituting group on the carbon atom of linking group A is alkyl (C1-C20), alkoxy (C1-C20) or amino or forms one or more ring structures incorporating one or more carbon atoms making up the linking group.
8. A catalyst according to claim 1 wherein the chiral diamine is of formula (II)
Figure US20070066850A1-20070322-C00040
wherein B is a linking group comprising one or two substituted or unsubstituted carbon atoms.
9. A catalyst according to claim 8 wherein R1, R2, R3, R4 are hydrogen, R5, R6, R7 and R8 are hydrogen or alkyl groups and B comprises C(CH3)2 or (CH3)(OCH3)C—C(CH3(OCH3).
10. A catalyst according to claim 8 wherein the chiral diamine is selected from 3-Aminomethyl-5-6-dimethoxy-5-6-Dimethyl[1,4]-dioxan-2-yi]-methylamine (DioBD) or 2,3-O-isopropylidenebutane 1,4 diamine (DAMTAR).
11. A catalyst according to claim 1 wherein the chiral diamine is of formula (III)
Figure US20070066850A1-20070322-C00041
wherein R′ is a protecting group.
12. A catalyst according to claim 11 wherein R1, R2 and R5 are hydrogen, R3 and R4 are hydrogen or alkyl, R7 and R8 are hydrogen, alkyl or aryl and R′ is selected from an alkyl, aryl, carboxylate, amido or sulphonate protecting group.
13. A catalyst according to claim 11 wherein the chiral diamine is 4-Amino-2-aminomethylpyrrolidine-1-carboxylic acid tent-butyl ester (PyrBD).
14. A catalyst according to claim 1 wherein the chiral diamine is of formula (IV)
Figure US20070066850A1-20070322-C00042
15. A catalyst according to claim 14 wherein R1, R2, R3, R4, R6, R7 are hydrogen and R5 and R8 are aryl or substituted aryl groups.
16. A catalyst according to claim 14 wherein the chiral diamine is Diphenyl-1,3-propanediamine (Dppn).
17. A catalyst according to claim 1 wherein the chiral diamine is of formula (V).
Figure US20070066850A1-20070322-C00043
wherein n=1 or 2.
18. A catalyst according to claim 17 wherein R5 and R8 are hydrogen.
19. A method for the asymmetric hydrogenation of ketones and imines comprising contacting a ketone or imine with a strong base and a chiral catalyst comprising the reaction product of a ruthenium compound, a chiral bis(phosphine) selected from P-Phos, tol-P-Phos or xyl-P-Phos and a chiral diamine of formula (I)
Figure US20070066850A1-20070322-C00044
in which R1, R2, R3 or R4 are independently hydrogen, a saturated or unsaturated alkyl, or cycloalkyl group, an aryl group, a urethane or sulphonyl group and R5, R6, R7 or Re are independently hydrogen, a saturated or unsaturated alkyl or cycloalkyl group, or an aryl group, at least one of R1, R2, R3 or R4 is hydrogen and A is a linking group comprising one or two substituted or unsubstituted carbon atoms.
20. The method according to claim 19, wherein the ketone is an alkyl ketone of formula RCOR′ in which R and R′ are substituted or unsubstituted, saturated or unsaturated C1-C20 alkyl or cycloalkyl which may be linked and form part of a ring structure.
US10/564,902 2003-07-15 2004-07-07 Catalysts Abandoned US20070066850A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/696,736 US8039675B2 (en) 2003-07-15 2010-01-29 Catalysts

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0316439.9 2003-07-15
GBGB0316439.9A GB0316439D0 (en) 2003-07-15 2003-07-15 Catalysts
PCT/GB2004/002938 WO2005007662A2 (en) 2003-07-15 2004-07-07 Biphosphine ruthenium complexes with chiral diamine ligande as catalysts

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/002938 A-371-Of-International WO2005007662A2 (en) 2003-07-15 2004-07-07 Biphosphine ruthenium complexes with chiral diamine ligande as catalysts

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/696,736 Continuation US8039675B2 (en) 2003-07-15 2010-01-29 Catalysts

Publications (1)

Publication Number Publication Date
US20070066850A1 true US20070066850A1 (en) 2007-03-22

Family

ID=27763778

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/564,902 Abandoned US20070066850A1 (en) 2003-07-15 2004-07-07 Catalysts
US12/696,736 Expired - Fee Related US8039675B2 (en) 2003-07-15 2010-01-29 Catalysts

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/696,736 Expired - Fee Related US8039675B2 (en) 2003-07-15 2010-01-29 Catalysts

Country Status (6)

Country Link
US (2) US20070066850A1 (en)
EP (2) EP1651657B1 (en)
AT (2) ATE370959T1 (en)
DE (2) DE602004018402D1 (en)
GB (1) GB0316439D0 (en)
WO (1) WO2005007662A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110152555A1 (en) * 2008-09-03 2011-06-23 Unitech Co., Ltd. Platinum complex and pharmaceutical composition containing the same

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1757571A1 (en) * 2005-07-29 2007-02-28 Laboratorios Del Dr. Esteve, S.A. Process for the homogeneous hydrogenation of ketones using ruthenium catalytic systems.
EP1792887A1 (en) * 2005-12-05 2007-06-06 Laboratorios Del Dr. Esteve, S.A. Process for the homogeneous hydrogenation of ketones using ruthenium catalytic systems
AU2007331340A1 (en) * 2006-12-12 2008-06-19 Bial-Portela & Ca, S.A. Catalytic process for asymmetric hydrogenation
GB0822064D0 (en) * 2008-12-03 2009-01-07 Johnson Matthey Plc Process for preparing cationic ruthenium complexes
JP4621285B2 (en) * 2009-01-19 2011-01-26 ユニーテック株式会社 Gold complex and pharmaceutical composition containing the same
CZ303113B6 (en) * 2010-03-16 2012-04-11 Zentiva, K.S. Process for preparing sitagliptin
CN102417523B (en) * 2010-09-27 2014-10-08 中山奕安泰医药科技有限公司 Nitrogen heterocycle ligand transition metal complex, and preparation and catalytic application thereof
JP5179628B2 (en) * 2011-07-15 2013-04-10 ユニーテック株式会社 Tetravalent platinum complex and pharmaceutical composition containing the same
JP6505685B2 (en) 2013-07-10 2019-04-24 モメンティブ パフォーマンス マテリアルズ インコーポレイテッドMomentive Performance Materials Inc. Continuous process for the preparation of thiocarboxylate silanes
CN105622345B (en) * 2014-11-04 2018-07-20 中国石油化工股份有限公司 A method of preparing beta-diol
CN105622346B (en) * 2014-11-04 2018-08-17 中国石油化工股份有限公司 A method of beta-diol is prepared by beta-diketon fixed bed hydrogenation
CN105541554B (en) * 2014-11-04 2018-04-13 中国石油化工股份有限公司 A kind of method by beta diketone Hydrogenation for β glycol
CN115850129B (en) * 2023-02-28 2023-05-16 凯莱英生命科学技术(天津)有限公司 Process for the preparation of (S) -1- (3-ethoxy-4-methoxyphenyl) -2- (methylsulfonyl) ethylamine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020095056A1 (en) * 2000-07-24 2002-07-18 Cobley Christopher James Ruthenium complexes and their use in asymmetric hydrogenation
US20030045727A1 (en) * 2000-02-08 2003-03-06 Seiji Nakano Process for preparing optically active secondary alcohols having nitrogenous or oxygenic functional groups
US6720439B1 (en) * 2001-09-28 2004-04-13 Nagoya Industrial Science Research Institute Synthesis of ruthenium-hydride complexes and preparation procedures of chiral alcohols and ketones

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763688A (en) 1994-12-07 1998-06-09 Research Development Corporation Of Japan Method for producing an alcohol
EP1030849A1 (en) 1997-11-12 2000-08-30 The Pennsylvania State University Transition metal-catalyzed reactions based on chiral amine oxazolinyl ligands
JP4052702B2 (en) 1997-12-26 2008-02-27 独立行政法人科学技術振興機構 Process for producing optically active alcohols
EP1146037B1 (en) 1999-01-18 2006-06-21 Nippon Soda Co., Ltd. Process for the preparation of optically active amino alcohols
JP3720235B2 (en) * 2000-03-14 2005-11-24 高砂香料工業株式会社 Method for producing optically active ruthenium phosphine complex and method for producing optically active alcohol using the complex
AU2001239442A1 (en) 2000-03-30 2001-10-15 Chirotech Technology Limited Ruthenium-diphosphine complexes and their use as catalysts
JP4286486B2 (en) 2001-01-15 2009-07-01 日本曹達株式会社 Ruthenium compound, diamine ligand and method for producing optically active alcohol
WO2002055477A1 (en) 2001-01-15 2002-07-18 Nippon Soda Co.,Ltd. RUTHENIUM COMPOUND, DIAMINE COMPOUND, AND PROCESS FOR PRODUCING β-AMINO -ALCOHOL
GB0129112D0 (en) * 2001-12-05 2002-01-23 Chirotech Technology Ltd Chiral ligands for asymmetric catalysis
JP3566955B2 (en) 2001-12-28 2004-09-15 関東化学株式会社 Novel ruthenium complex and method for producing alcohol compound using the same as catalyst
JPWO2004007506A1 (en) 2002-07-15 2005-11-10 日本曹達株式会社 Ruthenium compound, diamine ligand and method for producing optically active alcohol

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030045727A1 (en) * 2000-02-08 2003-03-06 Seiji Nakano Process for preparing optically active secondary alcohols having nitrogenous or oxygenic functional groups
US20020095056A1 (en) * 2000-07-24 2002-07-18 Cobley Christopher James Ruthenium complexes and their use in asymmetric hydrogenation
US6720439B1 (en) * 2001-09-28 2004-04-13 Nagoya Industrial Science Research Institute Synthesis of ruthenium-hydride complexes and preparation procedures of chiral alcohols and ketones

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110152555A1 (en) * 2008-09-03 2011-06-23 Unitech Co., Ltd. Platinum complex and pharmaceutical composition containing the same
US8501977B2 (en) 2008-09-03 2013-08-06 Unitech Co., Ltd. Platinum complex and pharmaceutical composition containing the same

Also Published As

Publication number Publication date
US20100197976A1 (en) 2010-08-05
WO2005007662A3 (en) 2005-03-24
EP1849792A1 (en) 2007-10-31
EP1651657B1 (en) 2007-08-22
EP1651657A2 (en) 2006-05-03
ATE417053T1 (en) 2008-12-15
WO2005007662A2 (en) 2005-01-27
EP1849792B1 (en) 2008-12-10
US8039675B2 (en) 2011-10-18
DE602004008478D1 (en) 2007-10-04
DE602004018402D1 (en) 2009-01-22
DE602004008478T2 (en) 2008-05-21
GB0316439D0 (en) 2003-08-20
ATE370959T1 (en) 2007-09-15

Similar Documents

Publication Publication Date Title
US8039675B2 (en) Catalysts
US7230134B2 (en) Method for the production of amines by reductive amination of carbonyl compounds under transfer-hydrogenation conditions
US7671225B2 (en) Ferrocenyl ligands for homogeneous, enantioselective hydrogenation catalysts
US20040063966A1 (en) Catalytic hydrogenation processes
US6528687B2 (en) Ruthenium complexes and their use in asymmetric hydrogenation
EP1276745B1 (en) Ruthenium-diphosphine complexes and their use as catalysts
EP2054363B1 (en) Asymmetric hydrogenation of 1,1,1-trifluoroacetone
US20100036127A1 (en) Process
US5159093A (en) Iridium-optically active phosphine complex and process for producing optically active alcohols using the same
MORIMOTO et al. Synthesis of Efficient Chiral Bisphosphine Ligands, Modified DIOPs,(4R, 5R)-4-(Diaryl-or dialkylphosphino) methyl-5-(diarylphosphino) methyl-2, 2-dimethyl-1, 3-dioxolanes, and Their Use in Rhodium (I)-Catalyzed Asymmetric Hydrogenations
WO2000041997A1 (en) Process for the preparation of optically active amino alcohols
US7906669B2 (en) Metallocene-based phosphorus chiral phosphines
WO2004007506A1 (en) Ruthenium compounds, diamine ligands, and process for preparation of optically active alcohols
US5324870A (en) Process for producing optically active 1-substituted-1,3-propanediols using ruthenium-phosphine complex as a catalyst
WO2008135386A1 (en) Chiral ligands of the n-heterocyclic carbene type for asymmetrical catalysis
US5686616A (en) Process for preparing an optically active amine
US7642357B2 (en) Iridium complexes
EP3877372A1 (en) Enantioselective process
JP3118061B2 (en) Production method of optically active hydroxylamine
EP0855390B1 (en) A process for producing optically active pyrrolidine derivatives
US20100069684A1 (en) Assymmetric hydrogeneration of prochiral compounds
US5210332A (en) Iridium-optically active phosphine complex and process for producing optically active alcohols using the same
JPH05194568A (en) New homochiral diphosphines
US20050043556A1 (en) Chiral ligands for asymmetric catalysis
JP2004099609A (en) Method for producing optically active 7-amino-5-azaspiro[2.4]heptane

Legal Events

Date Code Title Description
AS Assignment

Owner name: JOHNSON MATTHEY PLC, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HEMS, WILLIAM PATRICK;GRASA, GABRIELA ALEXANDRA;REEL/FRAME:018024/0490;SIGNING DATES FROM 20060116 TO 20060127

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE